Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1

Yin Z, Yu M, Ma T, *et al.* Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. *J Immunother Cancer* 2021;9:e001698. doi: 10.1136/jitc-2020-001698

This article has been corrected since it was first published. Amir Abaas Momtazi-Borojeni's affiliation has been updated to 'Department of Medical Biotechnology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran'.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2022;10:e001698corr2. doi:10.1136/jitc-2020-001698corr2